We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Implantable Device Reduces Migraine Headaches

By HospiMedica International staff writers
Posted on 05 Jul 2011
A novel implantable device reduces the number of migraine headaches by delivering mild electrical pulses to generate peripheral nerve stimulation (PNS) of the occipital nerve. More...


The St. Jude Medical (Little Canada, MN, USA) Genesis neurostimulator is a compact 8-contact primary cell implantable pulse generator (IPG) system with efficient circuitry and a high-capacity battery. The stopwatch-sized device is implanted in the upper chest or abdomen, and a lead wire extends to the occipital nerves at the back of the head. The system is designed to deliver constant electrical energy to these nerves, which studies suggest hold a role in how patients experience pain from migraine headaches. In a recent study, 157 patients who suffered an average of 26 headaches per month were implanted with the Genesis and then randomly assigned to an active or control group for 12 weeks.

The active group received stimulation immediately, while the control group did not receive stimulation until after the first 12 weeks. The results showed that the patients who received stimulation reported a 28% decrease in their number of headache days (7 fewer days per month), compared with the placebo group, which reported just one fewer day per month. At 12 weeks, 53% of patients in the active group ranked their relief as excellent or good, compared with 17% in the placebo group. The study was presented at the 15th International Headache Congress, held during June 2011 in Berlin (Germany).

"Many migraine patients have exhausted all current treatment options and often are disabled by the pain and frequency of migraine attacks," said lead author Stephen Silberstein, MD, director of the Jefferson Headache Center (Philadelphia, PA, USA), and past president of the American Headache Society. "Achieving a reduction in the number of days they suffer from headache and a significant improvement in their quality of life may be even more important than pain reduction alone."

Migraine is a debilitating condition characterized by moderate to severe headaches, and is about three times more common in women than in men. The typical migraine headache is unilateral pain and pulsating in nature, lasting from 4 to 72 hours; symptoms include nausea, vomiting, photophobia, phonophobia, and is aggravated by routine activity. Approximately one-third of people who suffer from migraine headaches perceive an aura--unusual visual, olfactory, or other sensory experiences that are a sign that the migraine will soon occur.

Related Links:
St. Jude Medical


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.